Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04337671
Other study ID # 2019HAHA
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2, 2018
Est. completion date December 28, 2019

Study information

Verified date April 2020
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study investigated the effect of 12 weeks of aerobic training on sleep quality and aerobic fitness in patients with Pulmonary arterial hypertension(PAH).


Description:

Thirty male PAH patients were included in the study. They were randomized into two equal groups; Training group (A) and Control group(B). Right ventricular systolic pressure (RVSP) measured using Doppler Echocardiography , Pittsburg sleep quality index (PSQI) questionnaire with the wrist worn actigraph used for the assessment of sleep disturbance, and Cardiopulmonary exercise testing (CPET) measurements included maximal heart rate and VO2max .All were measured before and after the study period for both groups.The training was a moderate intensity aerobic training on a bicycle ergometer (corresponding to 60% to 70% of the maximal heart rate they reach during peak oxygen uptake in the initial exercise test) for 30 to 45 min/day, 3 sessions/week for 12 weeks (36 sessions).


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 28, 2019
Est. primary completion date November 29, 2019
Accepts healthy volunteers No
Gender Male
Age group 45 Years to 65 Years
Eligibility Inclusion Criteria:

- Patients who were clinically stable and compensated under optimized medical therapy

- World health organization (WHO) Classification of functional class II to III PAH

- Patients with ejection fraction = 40%

- Non-smokers

- body mass index = 35 kg/m2

Exclusion Criteria:

- Any patient with respiratory failure

- unstable angina

- renal, hepatic or neuromuscular disorders

- history of syncopal attacks

- uncontrolled systemic hypertension

- peripheral vascular disease

- serious cardiac dysrhythmias on resting ECG

- evidence of severe COPD at pulmonary function testing,

- any known musculoskeletal or neurological conditions that might interfere with the execution or the assessment of the exercise

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Moderate intensity aerobic training
The exercise program consisted of 5 minutes warm-up, 15-30 minutes of moderate aerobic exercises and 10 minutes cool-down, respectively. Frequency: 3 sessions/week , and Duration:12 weeks.

Locations

Country Name City State
Egypt Faculty of Physical Therapy Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pulmonary artery systolic pressure (PASP) Pulsed Doppler Echocardiogram for assessing PASP as calculated from the gradient across the tricuspid valve using the modified Bernoulli equation. change from baseline at 12 weeks
Primary Subjective self-report questionnaire that assesses sleep quality The Pittsburgh Sleep Quality Index is a subjective self-report questionnaire that assesses sleep quality over a 1-month time interval in different populations It is 5 points score (0 means normal, 5 means severe sleep disturbance) change from baseline at 12 weeks
Primary Determining sleep patterns Determining sleep patterns by using actigraph to assess suspected certain sleep disorders, change from baseline at 12 weeks
Primary Measuring aerobic fitness Level of aerobic fitness assessed by using Cardiopulmonary exercise testing (CPET) through incremental exercise intensity until voluntary exhaustion. change from baseline at 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05056532 - Evaluation of Respiratory Muscle in Patient With Pulmonary Arterial Hypertension
Active, not recruiting NCT06003244 - High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT) N/A
Active, not recruiting NCT06072417 - HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level) N/A
Recruiting NCT02966665 - : Vascular Function in Health and Disease Phase 1
Recruiting NCT00502398 - Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension? N/A
Completed NCT04456998 - GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) Phase 2
Not yet recruiting NCT06035861 - Endothelial Cell Activation and Total Pulmonary Resistance in PAH N/A
Recruiting NCT03138863 - Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO) N/A
Recruiting NCT02102672 - Trimetazidine in Pulmonary Artery Hypertension Phase 2
Withdrawn NCT06122922 - Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN) Phase 2
Recruiting NCT03195543 - Assessment of Blood Coagulation Disorders in Patients With Pulmonary Hypertension
Completed NCT03198910 - Retrospective Data Analysis of Data From the Zurich PH Registry
Completed NCT03979482 - Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH
Active, not recruiting NCT05996302 - HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level) N/A
Active, not recruiting NCT06084559 - HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT) N/A
Withdrawn NCT02684786 - A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension Phase 1
Not yet recruiting NCT06258850 - REstoration of VItamin D in Pulmonary Arterial Hypertension Phase 4
Completed NCT04094272 - Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection
Active, not recruiting NCT01763112 - Training With Whole Body Vibration Device in Patients With PAH N/A
Completed NCT01581086 - Vascular Subphenotypes of Lung Disease in HIV & COPD N/A